Alnylam Pharmaceuticals(US:ALNY) ZACKSยท2025-10-30 15:30Core Insights - Alnylam Pharmaceuticals reported $1.25 billion in revenue for Q3 2025, marking a year-over-year increase of 149.4% and a surprise of +22.25% over the Zacks Consensus Estimate of $1.02 billion [1] - The company achieved an EPS of $2.90, a significant improvement from -$0.50 a year ago, resulting in an EPS surprise of +73.65% compared to the consensus estimate of $1.67 [1] Revenue Breakdown - Product revenues netted $851.08 million, exceeding the nine-analyst average estimate of $803.35 million, reflecting a year-over-year change of +102.6% [4] - Royalty revenue was reported at $46.2 million, slightly below the estimated $46.52 million, but still showing a +97.6% change year-over-year [4] - Net Product Revenue for Oxlumo was $52.83 million, surpassing the average estimate of $50.45 million, with a year-over-year increase of +31.4% [4] - Givlaari's Net Product Revenue was $73.87 million, compared to the average estimate of $79.51 million, indicating a +4% year-over-year change [4] - Onpattro's Net Product Revenue was $39.08 million, below the average estimate of $47.48 million, reflecting a year-over-year decrease of -22.3% [4] - Amvuttra's Net Product Revenue reached $685.3 million, exceeding the estimated $637.51 million, with a remarkable year-over-year increase of +165% [4] Stock Performance - Alnylam's shares have returned +4.6% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]